Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenzavvy in Women With ANOCA and Coronary Microvascular Disease
NCT06600178Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- Jul 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bexagliflozin in coronary microvascular disease (CMD) and Angina Pectoris (AP) (2 arms), sponsored by University of Virginia. Primary endpoint: Change in Coronary Flow Reserve at 12 weeks. Started Jul 2025; status: recruiting.
02
Drugs
bexagliflozin
03
Conditions
coronary microvascular disease (CMD)Angina Pectoris (AP)
Beyond the preview
Go deeper on NCT06600178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600178.